Biotech SPAC deal gets it to Nasdaq; AstraZeneca Phase 3 win in bone disease

June 29, 2026 10:34 AM EDT News Briefing Biotech SPAC deal gets it to Nas­daq; As­traZeneca Phase 3 win in chil­dren's bone dis­ease ENDPOINTS Plus news about Ale­bund Phar­ma­ceu­ti­cals, Re­genxbio and Ne­upho­ria Ther­a­peu­tics. 💸 A SPAC!: Ta­lawar Ther­a­peu­tics will land on the Nas­daq via a Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER